All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centersRandomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果